findmyKOL
Clinical trialNCT03852901CompletedPhase 1Interventional

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

SponsorNational Institute on Aging (NIA)Enrollment21EmpaglifozinHypoglycemic AgentsPhysiological Effects of DrugsSodium-Glucose Transporter 2 Inhibitors
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • National Institute on Aging, Clinical Research Unit

    Baltimore, Maryland, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Mar 2019
Primary completion
12 Nov 2020
Completion
13 Dec 2021
Last update posted
2 Aug 2022
Registered enrollment
21
Registry id
NCT03852901

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.